Nicaragua Post-Registration Changes: Seventeen Categories Under Chapter 9
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Chapter 9 of NTON 24001:2023 divides post-registration changes into seventeen categories and specifies, category by category, the documents that must be submitted. Three further items complete the chapter: item 18 lists five situations that require a new registration instead of a change, item 19 covers notification of discontinued presentations, and item 20 identifies who may sign the explanatory letter. For most categories the common core is four documents: the payment receipt, the official application form, the filing authorisation approved by SAJ, and the explanatory letter. Technical categories add supporting technical or clinical evidence on top of that base. Every category closes with a catch-all sentence allowing DDM to request any other technical or legal document it considers necessary to support the change.
- Seventeen change categories, each with its own document set, sit in Chapter 9 of NTON 24001:2023.
- Four documents form the shared base for most categories and can be maintained as reusable templates.
- Item 18 removes five product-identity changes from the change track and sends them to a new registration.
- Item 19 attaches discontinuation notices to the renewal moment rather than to a standalone filing route.
- Item 20 allows the explanatory letter to be signed by the holder, the legal manufacturer, or its representative in Nicaragua.
- Every category keeps a residual clause, so a complete checklist does not guarantee that nothing further will be requested.
2. Legal basis
The provisions below are drawn from Chapter 9 of NTON 24001:2023, published in La Gaceta No. 192 of 21 October 2024. The table groups the seventeen change categories as the standard presents them and records the additional documents attached to each group.
| Technical standard | NTON 24001:2023, “Tecnología de la salud. Dispositivos médicos. Requisitos para el Registro Sanitario” (La Gaceta No. 192, 21 October 2024) | Chapter 9, item 1 | Addition or change of model, reference number, code or packaging presentation: payment receipt, application form, CLV showing the added item, labels and packaging, explanatory letter, SAJ filing authorisation |
| Technical standard | NTON 24001:2023 | Chapter 9, item 2 | Change of address of the production plant of a foreign manufacturer within the same country: plus ISO 13485 certificate and labels and packaging showing the updated information |
| Technical standard | NTON 24001:2023 | Chapter 9, item 3 | Change of legal manufacturer: SAJ-approved filing authorisation and distribution authorisation, both showing the updated name; supporting document issued by the competent authority in the country of origin; explanatory letter |
| Technical standard | NTON 24001:2023 | Chapter 9, items 4 to 7 | Four name-change categories: item 4 covers cases where the manufacturer, holder, packager and/or legal manufacturer are the same entity; items 6 and 7 cover the manufacturer or packager, and the holder or legal manufacturer, respectively |
| Technical standard | NTON 24001:2023 | Chapter 9, item 8 | Change of holder: explanatory letter issued by the legal manufacturer, duly apostilled |
| Technical standard | NTON 24001:2023 | Chapter 9, items 9 to 13 | Changes to service life, indications for use, contraindications or precautions, technical specifications, and manuals, inserts or instructions for use; technical categories require supporting technical or clinical data |
| Technical standard | NTON 24001:2023 | Chapter 9, items 14 and 15 | Change of analytical methodology, with the new finished-product analytical methodology; software change or update, with technical information on the modifications made to the software |
| Technical standard | NTON 24001:2023 | Chapter 9, items 16 and 17 | Change or addition of a distributor, with a copy of the DDM-approved document; change of type, material or design of the label or packaging, with a complete stability study showing that the change in packaging material does not affect the product |
3. Expert insights
The first point is organisational. Because four documents recur across most categories, the efficient way to run change management is to prepare those four first and then add the category-specific technical material. Most changes need nothing more than that base plus one or two supporting documents.
The second point concerns signatures. Item 20 states that the explanatory letter may be issued by the holder, by the legal manufacturer of the product, or by its legal representative in Nicaragua. Any one of the three is sufficient; all three signatures are not required. For overseas manufacturers this removes a recurring bottleneck, because the letter can be issued locally when the representative holds the necessary authority.
The third point is authentication. Item 8, the change of holder, is the category that requires legalisation of a foreign document: “Carta explicativa de parte del fabricante legal del cambio de titular debidamente apostillada”. The apostille is mandatory. Together with item 3, which requires a supporting document from the competent authority in the country of origin, it forms the two extraterritorial requirements that weigh most heavily on change filings.
The fourth point is packaging. Item 17 requires a complete stability study demonstrating that a change of packaging material does not affect the product. This is the most technically demanding of the seventeen categories, and it ties packaging design directly to stability data: a change of packaging material is not a change of artwork. Teams that treat it as a design update will find the file incomplete.
The fifth point is software. Item 15, covering a software change or update, echoes rule 11 of Annex B on software classification and connects to the SaMD definition that Adenda 2026-05 proposes to add. A software change requires only technical information on the modifications made, which is lighter than most technical categories; the harder question is whether a given modification counts as a change at all, and that threshold has to be read against the device class.
The sixth point is discontinuation. Item 19 attaches the notification of discontinued models, reference numbers or packaging presentations to the renewal moment. There is therefore no separate discontinuation filing channel, and information about a discontinued presentation enters the system officially only when the renewal window opens.
The seventh point is the residual clause. Each category ends with “La Dirección de Dispositivo Médicos puede solicitar cualquier otro documento técnico o legal que estime necesario para soportar el cambio”. The list is therefore not closed. Matching the checklist is a necessary condition for a complete filing, not a guarantee that no further request will follow.
4. Practical recommendations
- Build a change classification table first: decide whether the case falls under items 1 to 17 of Chapter 9 or under the five re-registration situations in item 18. An error at this step propagates through the whole filing.
- Organise documents as a four-document base plus category add-ons, and keep the base as reusable templates.
- Where the holder changes, arrange the apostille of the legal manufacturer’s explanatory letter in advance, as required by Chapter 9, item 8.
- Where the legal manufacturer changes, prepare in parallel the supporting document from the competent authority in the country of origin, as required by Chapter 9, item 3.
- Complete the stability study before filing a change of packaging material, in line with Chapter 9, item 17.
- Report discontinued models, reference numbers or presentations together with the renewal submission, in line with Chapter 9, item 19.
5. Verification checklist
- □ The change category has been determined against items 1 to 17 and item 18 of Chapter 9.
- □ The four common documents are ready: payment receipt, application form, SAJ filing authorisation and explanatory letter.
- □ Where the holder changes, the legal manufacturer’s explanatory letter has been apostilled.
- □ Where the legal manufacturer changes, the supporting document from the authority in the country of origin has been obtained.
- □ A change of packaging material is supported by a complete stability study.
- □ Discontinued models, reference numbers or presentations are included in the renewal notification.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us